Eisai's Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annu... ( WOODCLIFF LAKE N.J. May 15 /- Eis...)

Eisai's Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annual Meeting

Date:5/15/2008

WOODCLIFF LAKE, N.J., May 15 /PRNewswire/ -- Eisai Corporation of North America announced today that results from 16 clinical data abstracts about compounds in the company's oncology pipeline, product portfolio and preclinical oncology research have been accepted for presentation at the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO), taking place in Chicago from May 30 to June 3, 2008.

A wide variety of abstracts on Eisai marketed products and investigational compounds will showcase research focused on metastatic breast cancer, lung cancer, ovarian cancer, brain cancer, mesothelioma, pancreatic cancer, myelodysplastic syndromes and other types of cancer, as well as supportive care to aid those currently undergoing treatment for cancer.

"Eisai's commitment to oncology is clearly translating into the substantial growth of our pipeline," said Haruo Naito, President and CEO, Eisai Co., Ltd. "Eisai's focus on becoming a global leader in oncology reflects our human health care mission to satisfy unmet medical needs and increase benefits to patients and their families."

The following Eisai abstracts are accepted for presentation at this year's ASCO meeting.

Product Abstract Details Location Details

MORAb-003 Exploratory Phase II Efficacy June 1, 2008

(farletuzumab) Study of MORAb-003, a Monoclonal 4:30-4:45 p.m.

Abstract No: 5500 Antibody against Folate Receptor Location: S406

Alpha, in Platinum-Sensitive (Vista Room)

Ovarian Cancer in First Relapse

Oral Presentation

E7080 A phase I study of E7080 in May 31, 2008

Abstract No: 3526 patients with advanced 8:00 a.m.

malignancies -12:00 p.m.

'/>"/>

0

GOOD

Page: 1 2 3 4 5 6 7 8
Related medicine technology :

1. GeoVax Secures $10 Million Financing Commitment
2. On Second Anniversary, Compendia Bioscience Announces Significant Revenue Growth, Completion of Product Milestone and Expansion of Pharma Customer Commitments
3. Medivation Announces Presentation of MDV3100 Clinical Data in Patients With Castration-Resistant Prostate Cancer at 44th American Society of Clinical Oncology Annual Meeting
4. BiPar Sciences Announces Clinical Data Presentations on Lead PARP Inhibitor, BSI-201, at 40th American Society of Clinical Oncology Annual Meeting
5. Poniard to Present Clinical Data From Picoplatin Trials in Multiple Tumor Types at American Society of Clinical Oncology 2008 Annual Meeting
6. Release of Cytopia Abstract for CYT997 Oral Presentation at American Society of Clinical Oncology
7. Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting
8. Champions Biotechnology and Concordia Pharmaceuticals Complete Service Agreement and Begin Preclinical Evaluation of Oncology Drugs
9. Medarex Announces Presentations at Annual Meeting of the American Society of Clinical Oncology
10. GlaxoSmithKline Reports Further Progress of Oncology Portfolio
11. Roche Gains Access to Important Oncology Target With Potential for Treating Major Cancers Such as Breast and Lung; First Drug Candidate in Phase I Clinical Testing

Post Your Comments:

Eisai's Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annu...( WOODCLIFF LAKE N.J. May 15 /- Eis...),Health